Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0000950170-25-061848
Filing Date
2025-05-01
Accepted
2025-05-01 16:15:19
Documents
51
Period of Report
2025-03-31

Document Format Files

Seq Description Document Type Size
1 10-Q kura-20250331.htm   iXBRL 10-Q 2004136
2 EX-31.1 kura-ex31_1.htm EX-31.1 11983
3 EX-32.1 kura-ex32_1.htm EX-32.1 10090
  Complete submission text file 0000950170-25-061848.txt   6854211

Data Files

Seq Description Document Type Size
4 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT kura-20250331.xsd EX-101.SCH 853135
54 EXTRACTED XBRL INSTANCE DOCUMENT kura-20250331_htm.xml XML 1057248
Mailing Address 12730 HIGH BLUFF DRIVE, SUITE 400 SAN DIEGO CA 92130
Business Address 12730 HIGH BLUFF DRIVE, SUITE 400 SAN DIEGO CA 92130 (858) 500-8800
Kura Oncology, Inc. (Filer) CIK: 0001422143 (see all company filings)

EIN.: 611547851 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-37620 | Film No.: 25903298
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)